CLAIMS

1. A compound of formula I:



(I);

or any pharmaceutically-acceptable salt thereof, wherein:

X^1 is N or -CR^6;

R^1 is -CN, or a group -Z-R^{12} wherein Z is -$C_{0\text{-}4}$alk-, -NR^{11}-, -$NR^{11}SO_2$-, -SO_2NR^{11}-, -NR^{11}-S(=O)(=NH), -S(=O)(=NH)-, -S-, -S(=O)-, -SO_2-, $C_{0\text{-}4}$alk-O-, -(C=O)-, -(C=O)NR^{11}-,
-C=N(OH)-, or -NR^{11}(C=O); or

the group -Z-R^{12} is -N=S(=O)-$(R^{12})_2$, wherein the two R^{12} pair can alternatively combine with the sulfur atom attached to each of them to form a saturated or partially-saturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0, 1, 2 or 3 N atoms and 0, 1, or 2 atoms selected from O and S;

R^2 is halo or a group –Y-R^{13}, wherein Y is -$C_{0\text{-}4}$alk-, -N($C_{0\text{-}1}$alk)-$C_{0\text{-}4}$alk-, -C(=O)NR^aR^a($C_{1\text{-}4}$alk), -O-$C_{0\text{-}4}$alk-, S, S=O, $S(=O)_2$, -SO_2NR^{13}, or -S(=O)(=NH)-;

R^3 is H, $C_{1\text{-}4}$alk, or $C_{1\text{-}4}$haloalk;

R^4 is H, halo, R^{4a} or R^{4b};

R^5 is H, halo, $C_{1\text{-}8}$alk, or $C_{1\text{-}4}$haloalk;

R^6 is H, halo, $C_{1\text{-}8}$alk, $C_{1\text{-}4}$haloalk, -O-$C_{1\text{-}8}$alk, or -O-$R^{6a;}$ wherein R^{6a} is a saturated or partially-saturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0, 1, 2 or 3 N atoms and 0, 1, or 2 atoms selected from O and S;

R^7 is H, halo, $C_{1\text{-}8}$alk, or $C_{1\text{-}4}$haloalk;

R^8 is H, halo, $C_{1\text{-}8}$alk, $C_{1\text{-}4}$haloalk, -OH, -O-R^{8a}, or -O-R^{8b};

R^9 is H, halo, $C_{1\text{-}8}$alk, or $C_{1\text{-}4}$haloalk;

R^x is selected from the group consisting of ,

, , and ;

Each of R^{10a}, R^{10b}, R^{10c}, R^{10d}, R^{10e}, R^{10f}, R^{10g}, R^{10h}, R^{10i}, and R^{10j} is H, halo, R^{10k}, or R^{10l};

or alternatively, each of R^{10a} and R^{10b} pair, R^{10c} and R^{10d} pair, R^{10e} and R^{10f} pair, R^{10g} and R^{10h} pair, or R^{10i} and R^{10j} pair, independently, can combine with the carbon atom attached to each of them to form a saturated or partially-saturated 3-, 4-, 5-, 6-membered monocyclic ring spiro to the R^x ring; wherein said 3-, 4-, 5-, 6-membered monocyclic ring contains 0, 1, 2 or 3 N atoms and 0, 1, or 2 atoms selected from O and S, and further wherein said 3-, 4-, 5-, 6-membered monocyclic ring is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, $C_{1\text{-}6}$alk, $C_{1\text{-}4}$haloalk, -OR^a, -$OC_{1\text{-}4}$haloalk, CN, -NR^aR^a, or oxo;

R^{11} is H, R^{11a}, or R^{11b};

R^{12} is H, R^{12a}, or R^{12b};

R^{13} is R^{13a} or R^{13b};

R^{4a}, R^{8a}, R^{10k}, R^{11a}, R^{12a}, and R^{13a} is independently, at each instance, selected from the group consisting of a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0, 1, or 2 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, $C_{1\text{-}6}$alk, $C_{1\text{-}4}$haloalk, -OR^a, -$OC_{1\text{-}4}$haloalk, CN, -$C(=O)R^b$, -$C(=O)OR^a$, -$C(=O)NR^aR^a$, -$C(=NR^a)NR^aR^a$, -$OC(=O)R^b$, -$OC(=O)NR^aR^a$, -$OC_{2\text{-}6}$alkNR^aR^a, -$OC_{2\text{-}6}$alkOR^a, -SR^a, -$S(=O)R^b$, -$S(=O)_2R^b$, -$S(=O)_2NR^aR^a$, -NR^aR^a, -$N(R^a)C(=O)R^b$, -$N(R^a)C(=O)OR^b$,-$N(R^a)C(=O)NR^aR^a$, -$N(R^a)C(=NR^a)NR^aR^a$, -$N(R^a)S(=O)_2R^b$, -$N(R^a)S(=O)_2NR^aR^a$, -$NR^aC_{2\text{-}6}$alkNR^aR^a, -$NR^aC_{2\text{-}6}$alkOR^a,

-C_{1-6}alkNR^aR^a, -C_{1-6}alkOR^a, -C_{1-6}alk$N(R^a)C(=O)R^b$, -C_{1-6}alk$OC(=O)R^b$, -C_{1-6}alk$C(=O)NR^aR^a$,

-C_{1-6}alk$C(=O)OR^a$, R^{14}, and oxo;

R^{4b}, R^{8b}, R^{10l}, R^{11b}, R^{12b}, and R^{13b} is independently, at each instance, selected from the group consisting of C_{1-6}alk substituted by 0, 1, 2, 3, 4, or 5 group(s) selected from F, Cl, Br, -OR^a, -OC_{1-4}haloalk, or CN;

R^{14} is independently, at each instance, selected from the group consisting of a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, C_{1-6}alk, C_{1-4}haloalk, -OR^a,

-OC_{1-4}haloalk,

CN, -$C(=O)R^b$, -$C(=O)OR^a$, -$C(=O)NR^aR^a$, -$C(=NR^a)NR^aR^a$, -$OC(=O)R^b$, -$OC(=O)NR^aR^a$,

-OC_{2-6}alkNR^aR^a, -OC_{2-6}alkOR^a, -SR^a, -$S(=O)R^b$, -$S(=O)_2R^b$, -$S(=O)_2NR^aR^a$, -NR^aR^a, -$N(R^a)C(=O)R^b$,

-$N(R^a)C(=O)OR^b$,-$N(R^a)C(=O)NR^aR^a$, -$N(R^a)C(=NR^a)NR^aR^a$, -$N(R^a)S(=O)_2R^b$, -$N(R^a)S(=O)_2NR^aR^a$,

-NR^aC_{2-6}alkNR^aR^a, -NR^aC_{2-6}alkOR^a, -C_{1-6}alkNR^aR^a, -C_{1-6}alkOR^a, -C_{1-6}alk$N(R^a)C(=O)R^b$,

-C_{1-6}alk$OC(=O)R^b$, -C_{1-6}alk$C(=O)NR^aR^a$, -C_{1-6}alk$C(=O)OR^a$, and oxo;

R^a is independently, at each instance, H or R^b; and

R^b is independently, at each instance, C_{1-6}alk, phenyl, or benzyl, wherein the C_{1-6}alk is being substituted by 0, 1, 2 or 3 substituents selected from halo, -OH, -OC_{1-4}alk, -NH_2, -NHC_{1-4}alk,

-$OC(=O)C_{1-4}$alk, or -$N(C_{1-4}alk)C_{1-4}$alk; and the phenyl or benzyl is being substituted by 0, 1, 2 or 3 substituents selected from halo, C_{1-4}alk, C_{1-3}haloalk, -OH, -OC_{1-4}alk, -NH_2, -NHC_{1-4}alk, -$OC(=O)C_{1-4}$alk, or -$N(C_{1-4}alk)C_{1-4}$alk.

2. The compound of claim 1, or the pharmaceutically-acceptable salt thereof, wherein X^1 is N; having the formula (Ia):



(Ia).

3. The compound of claim 1, or the pharmaceutically-acceptable salt thereof, wherein X^1 is -CR^6; having the formula (Ib):



(Ib).

4. The compound of claim 1, or the pharmaceutically-acceptable salt thereof, wherein R^3 is H or methyl.

5. The compound of any one of claims 1 to 4, or the pharmaceutically-acceptable salt thereof, wherein each of R^{10c}, R^{10d}, R^{10e}, R^{10f}, R^{10g}, R^{10h}, R^{10i}, and R^{10j} is H, halo, $C_{1\text{-}6}$alk, or $C_{1\text{-}4}$haloalk; and each of R^{10a} and R^{10b} pair combine with the carbon atom attached to each of them form a saturated 3-, 4-, or 5-membered monocyclic ring spiro to the R^x ring; wherein said ring contains 0, 1, 2 or 3 N atoms and 0, 1, or 2 atoms selected from O and S.

6. The compound of any one of claims 1 to 5, or the pharmaceutically-acceptable salt thereof, wherein each of R^{10c}, R^{10d}, R^{10e}, R^{10f}, R^{10g}, R^{10h}, R^{10i}, and R^{10j} is H, methyl, or ethyl; and each of R^{10a} and R^{10b} pair combine with the carbon atom attached to each of them form a cyclopropyl, cyclobutyl, or cyclopentyl ring spiro to the R^x ring.

7. The compound of any one of claims 1 to 6, or the pharmaceutically-acceptable salt thereof, wherein the group  is selected from:



.

8. The compound of any one of claims 1 to 7, or the pharmaceutically-acceptable salt thereof, wherein the group  is .

9. The compound of any one of claims 1 to 8, or the pharmaceutically-acceptable salt thereof, wherein R^1 is -CN, or a group -Z-R^{12}, wherein Z is a bond, -NH-, -$NHSO_2$-, -SO_2NH-,
-S(=O)(=NH)-, -S-, -S(=O)-, -SO_2-, -(C=O)-, -(C=O)NH-, or -NH(C=O)-; and

R^{12} is selected from:

(a) H;

(b) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxiranyl, oxetanyl, tetrahydrofuranyl, azetidinyl, imidazolyl, morpholinyl, pyrrolidinyl, piperazinyl,



; wherein each said ring is substituted by 0, 1, 2 or 3 group(s) selected from wherein each ring is substituted by 0, 1, 2 or 3 OH, F,

methyl, -CH_2OH, -$C(=O)OCH_3$,
-$C(=O)OC(CH_3)_3$, NH_2, CN, and oxo; or

(c) C_{1-6}alk substituted by 0, 1, 2 or 3 OH, F, -$C(=O)OCH_3$, -NH_2, -$NH(CH_3)$, or
-$N(CH_3)_2$.

10. The compound of any one of claims 1 to 9, or the pharmaceutically-acceptable salt thereof, wherein R^1 is -CN, or a group -Z-R^{12}, wherein Z is a bond, -NH-, -$NHSO_2$-, -SO_2NH-,
-S(=O)(=NH)-, -S-, -S(=O)-, -SO_2-, -(C=O)-, -(C=O)NH-, or -NH(C=O)-; and

(a) R^{12} is H;

(b) R^{12} is oxetanyl, cyclopropyl; or

(c) R^{12} is C_{1-6}alk substituted by 0, 1, 2 or 3 OH group(s).

11. The compound of any one of claims 1 to 8, or the pharmaceutically-acceptable salt thereof, wherein the group -Z-R^{12} is -N=S(=O)-$(R^{12})_2$, wherein the two R^{12} pair can alternatively combine with the sulfur atom attached to each of them to form a saturated or partially-saturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0, 1, 2 or 3 N atoms and 0, 1, or 2 atoms selected from O and S; which is selected from:


, , or .

12. The compound of any one of claims 1 to 10, or the pharmaceutically-acceptable salt thereof, wherein R^1 is a group -Z-R^{12}, wherein Z is -$NHSO_2$- or -SO_2NH-; and R^{12} is oxetanyl, cyclopropyl, or R^{12} is C_{1-6}alk substituted by 0, 1, 2 or 3 OH group(s).

13. The compound of any one of claims 1 to 10 or 12, or the pharmaceutically-acceptable salt thereof, wherein R^1 is a group -Z-R^{12}, wherein Z is -$NHSO_2$- and R^{12} is –CH_2-CH_2-OH.

14. The compound of any one of claims 1 to 13, or the pharmaceutically-acceptable salt thereof, wherein R^2 is halo or a group –Y-R^{13}, wherein Y is a bond, -NH-, -NH-$(CH_2)_{0-4}$-, or -O-$(CH_2)_{0-4}$; and

R^{13} is a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or

4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, C_{1-6}alk, C_{1-4}haloalk, -OH, -OC_{1-4}haloalk, CN, R^{14}, and oxo; or

R^{13} is C_{1-6}alk substituted by 0, 1, 2, 3, 4, or 5 group(s) selected from F, Cl, Br, -OH, -OC_{1-4}haloalk, or CN.

15. The compound of any one of claims 1 to 14, or the pharmaceutically-acceptable salt thereof, wherein R^2 is a saturated 5- or 6-membered monocyclic ring wherein each said ring contains 0, 1, or 2 N atoms and 0 or 1 O atom, and wherein each said ring is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, C_{1-6}alk, C_{1-4}haloalk, -OH, -OC_{1-4}haloalk, CN, R^{14}, and oxo.

16. The compound of any one of claims 1 to 15, or the pharmaceutically-acceptable salt thereof, wherein

R^2 is (a) halo; (b) a group –Y-R^{13}, wherein Y is a bond; and R^{13} is morpholinyl, piperidinyl, azetidinyl, pyrrolidinyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperazinyl, tetrahydrofuranyl,



, , , , , or , ; wherein each said ring is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, methyl, CF_3, -OH, $-OCHF_2$, CN, and oxo; or

(c) a group –Y-R^{13}, wherein Y is NH, -O-, -O-(CH_2)-, -O-(CH_2)-(CH_2)-, or -O-(CH_2)-(CH_2)-(CH_2)-, and wherein R^{13} is ; ; ; or R^{13} is C_{1-6}alk substituted by 0, 1, 2, 3, 4, or 5 group(s) selected from F, Cl, Br, methyl, CF_3, -OH, or CN.

17. The compound of any one of claims 1 to 16, or the pharmaceutically-acceptable salt thereof, wherein R^2 is morpholinyl or piperidinyl substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, methyl, CF_3, -OH, $-OCHF_2$, CN, or oxo.

18. The compound of any one of claims 1 to 17, or the pharmaceutically-acceptable salt thereof, of any one of claims 1-4, or the pharmaceutically-acceptable salt thereof, wherein R^2 is morpholinyl substituted by 1, 2 or 3 methyl group(s).

19. The compound of any one of claims 1 to 17, or the pharmaceutically-acceptable salt thereof, wherein R^2 is piperidinyl substituted by 1, 2 or 3 fluoro group(s).

20. The compound of any one of claims 1 to 16, or the pharmaceutically-acceptable salt thereof, wherein R^2 is

; ; ; or .

21. The compound of any one of claims 1 to 13, or the pharmaceutically-acceptable salt thereof, wherein Z is a bond, -NH-, $-NHSO_2$-, $-SO_2NH$-, -S(=O)(=NH)-, -S-, -S(=O)-, $-SO_2$-, -(C=O)-, -(C=O)NH-, or -NH(C=O)-.

22. The compound of any one of claims 1 to 13 or 21, or the pharmaceutically-acceptable salt thereof, wherein R^{12} is selected from (a) H; (b) C_{1-6}alk substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, -OH, $-OCH_3$, or cyclopropyl; or (c) a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-

membered monocyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, $C_{1\text{-}6}$alk, $C_{1\text{-}4}$haloalk, -$C_{1\text{-}6}$alkOH,
-OH, -OCH_3, -NH_2, or oxo.

23. The compound of any one of claims 1 to 13 or 21 to 22, or the pharmaceutically-acceptable salt thereof, wherein R^{12} is selected from cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, or 1,3,4-oxathiazinanyl.

24. The compound of any one of claims 1 to 23, or the pharmaceutically-acceptable salt thereof, wherein R^4 is selected from (a) H; (b) $C_{1\text{-}6}$alk substituted by 0, 1, 2 or 3 OH group(s); or (c) cyclopropyl.

25. The compound of any one of claims 1 to 24, or the pharmaceutically-acceptable salt thereof, wherein R^4 is H or methyl.

26. The compound of any one of claims 1 to 25, or the pharmaceutically-acceptable salt thereof, wherein R^5 is H.

27. The compound of any one of claims 1 or 3 to 26, or the pharmaceutically-acceptable salt thereof, wherein R^6 is H or F.

28. The compound of any one of claims 1 to 27, or the pharmaceutically-acceptable salt thereof, wherein R^7 is H or F.

29. The compound of any one of claims 1 to 28, or the pharmaceutically-acceptable salt thereof, wherein R^8 is H.

30. The compound of any one of claims 1 to 29, or the pharmaceutically-acceptable salt thereof, wherein R^9 is H.

31. The compound of any one of claims 1 to 30, selected from:

Ex. #	Chemical Structure	Name
1		*N*-(2-((1-Hydroxy-2-methylpropan-2-yl)amino)-6-methylpyrimidin-4-yl)-4-(methylsulfonyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

Ex. #	Chemical Structure	Name
1-7		N-(2-((1-hydroxy-2-methylpropan-2-yl)amino)-6-methylpyrimidin-4-yl)-4-(N-(3-methyloxetan-3-yl)sulfamoyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
2		*N*-(2-(2-Hydroxypropan-2-yl)pyrimidin-4-yl)-4-(*N*-(3-methyloxetan-3-yl)sulfamoyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
2-4		*N*-(2-(4,4-Difluoropiperidin-1-yl)pyridin-4-yl)-4-(*N*-(3-methyloxetan-3-yl)sulfamoyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
2-8		*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((1-methylcyclopropane)-1-sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
3		(*R*)-4-((2-Hydroxyethyl)sulfonamido)-*N*-(6-methyl-2-(2-methylmorpholino)pyrimidin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

Ex. #	Chemical Structure	Name
4		*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
5-1		(*R*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxy-1-methylethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
5-2		(*S*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxy-1-methylethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
6-7		*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-(ethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
7		*N*-(2-(3,3-Difluoroazetidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

Ex. #	Chemical Structure	Name
8-1		(*R*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-5-fluoro-4-((2-hydroxy-1-methylethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
8-2		(*S*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-5-fluoro-4-((2-hydroxy-1-methylethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
10-1		(*R*)-*N*-(2-(3,3-Difluoroazetidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxypropyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
10-2		(*S*)-*N*-(2-(3,3-Difluoroazetidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxypropyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
12		*N*-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

Ex. #	Chemical Structure	Name
13-1		(*S*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((1-hydroxypropan-2-yl)sulfonyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
13-2		(*R*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((1-hydroxypropan-2-yl)sulfonyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
14		*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((1-hydroxy-2-methylpropan-2-yl)sulfonyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
15		*N*-(2-(4,4-Difluorocyclohexyl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
16-1		(*R*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-fluoro-1-(hydroxymethyl)ethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

Ex. #	Chemical Structure	Name
16-2		(*S*)-*N*-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-fluoro-1-(hydroxymethyl)ethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
17		*N*-(2-(4,4-Difluoropiperidin-1-yl)pyridin-4-yl)-4-(N-(2-hydroxyethyl)sulfamoyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
18-1		2-(6-Azaspiro[2.5]octan-6-yl)-4-(*R*-cyclopropylsulfonimidoyl)-*N*-(2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl)benzamide
18-2		2-(6-Azaspiro[2.5]octan-6-yl)-4-(*S*-cyclopropylsulfonimidoyl)-*N*-(2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl)benzamide
20		(N^1-(2-(4,4-Difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)terephthalamide

Ex. #	Chemical Structure	Name
21		4-(Azetidin-3-ylsulfonyl)-*N*-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
22		*N*-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((1-methylazetidin-3-yl)sulfonyl)-2-(6-azaspiro[2.5]octan-6-yl)benzamide

; or any pharmaceutically-acceptable salt thereof.

32. A pharmaceutical composition comprising the compound according to any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

33. A method of treating a condition that may be treated with KIF18a inhibitors, the method comprising administering to a patient in need thereof a therapeutically effective amount of the compound in accordance with any one of claims 1 to 31, or the composition according to claim 32.

34. The method of Claim 33, wherein said condition is cancer selected from the group consisting of (a) a solid or hematologically derived tumor selected from cancer of the cancer of the bladder, endometrial, lung squamous cell, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall-bladder, brain, head and neck, ovary, pancreas, stomach, cervix, thyroid, prostate and skin, (b) a hematopoietic tumor of lymphoid lineage selected from leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma, (c) a hematopoietic tumor of myeloid lineage selected from acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia (d) a tumor of mesenchymal origin selected from fibrosarcoma and rhabdomyosarcoma, (e) a tumor of the central and peripheral nervous system selected

from astrocytoma, neuroblastoma, glioma and schwannoma, or (f) a melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer or Kaposi's sarcoma.

35. A method of reducing the size of a solid tumor in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of the compound in accordance with any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, or the composition according to claim 32.

36. A method of treating a cell proliferation disorder in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of the compound in accordance with any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, or the composition according to claim 32.

37. A method of inhibiting KIF18A in a cell, comprising contacting the cell with a compound, or pharmaceutically acceptable salts thereof, in accordance with any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, or the composition according to claim 32.

38. Use of the compound or the pharmaceutically acceptable salt of said compound according to any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Claim 32, in the preparation of a medicament for treating a condition that may be treated with KIF18a inhibitors.

39. Use of the compound or the pharmaceutically acceptable salt of said compound according to claim 38 wherein the condition is cancer selected from the group consisting of (a) a solid or hematologically derived tumor selected from cancer of the cancer of the bladder, endometrial, lung squamous cell, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall-bladder, brain, head and neck, ovary, pancreas, stomach, cervix, thyroid, prostate and skin, (b) a hematopoietic tumor of lymphoid lineage selected from leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma, (c) a hematopoietic tumor of myeloid lineage selected from acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia (d) a tumor of mesenchymal origin selected from fibrosarcoma and rhabdomyosarcoma, (e) a tumor of the central and peripheral nervous system selected from astrocytoma,

neuroblastoma, glioma and schwannoma, or (f) a melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer or Kaposi's sarcoma.

40. Use of the compound or the pharmaceutically acceptable salt of said compound according to any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Claim 32, in the preparation of a medicament for reducing the size of a solid tumor in a subject.

41. Use of the compound or the pharmaceutically acceptable salt of said compound according to any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Claim 32, in the preparation of a medicament for treating a cell proliferation disorder in a subject.

42. Use of the compound or the pharmaceutically acceptable salt of said compound according to any one of claims 1 to 31, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Claim 32, in the preparation of a medicament for inhibiting KIF18A in a cell.